Inactive Instrument

Johnson & Johnson Share Price Buenos Aires S.E.

Equities

DJNJ3D

ARDEUT112687

Pharmaceuticals

Financials

Sales 2024 * 8.83TCr 78,89500Cr 7,34500Cr Sales 2025 * 9.08TCr 81,05000Cr 7,54600Cr Capitalization 35TCr 3,15,86300Cr 29,40600Cr
Net income 2024 * 2.2TCr 19,68100Cr 1,83200Cr Net income 2025 * 2.31TCr 20,62100Cr 1,92000Cr EV / Sales 2024 * 3.92 x
Net cash position 2024 * 699.71Cr 6,24800Cr 58TCr Net cash position 2025 * 1.98TCr 17,71900Cr 1,65000Cr EV / Sales 2025 * 3.68 x
P/E ratio 2024 *
16.3 x
P/E ratio 2025 *
15.4 x
Employees 1,31,900
Yield 2024 *
3.28%
Yield 2025 *
3.43%
Free-Float 77.08%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 61 01/89/01
Director of Finance/CFO 57 01/98/01
Chief Tech/Sci/R&D Officer 58 05/19/05
Members of the board TitleAgeSince
Director/Board Member 70 25/19/25
Director/Board Member 72 19/14/19
Director/Board Member 70 22/09/22
More insiders
Date Price Change Volume
27/24/27 1,250 -.--% 9
23/24/23 1,250 -.--% 11

End-of-day quote Buenos Aires S.E., April 26, 2024

More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
1st Jan change Capi.
+37.66% 73TCr
+15.67% 33TCr
-0.23% 28TCr
+13.47% 24TCr
+7.35% 21TCr
-6.42% 20TCr
+3.88% 16TCr
-2.10% 16TCr
-1.31% 12TCr
Other Pharmaceuticals